Curran Simpson - 01 Jul 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RGNX
Reported as of: 01 Jul 2025
Net transaction value: -$38,689
SEC form: 4
Accepted by SEC: 03 Jul 2025, 18:53:52 UTC
Prior SEC filing: 14 Jan 2025
Next SEC filing: 12 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Curran Simpson filed Form 4 for REGENXBIO Inc. (RGNX) on 03 Jul 2025.

Key facts

This page summarizes Curran Simpson's Form 4 filing for REGENXBIO Inc. (RGNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 18:53.

Change

Previous filing in this sequence was filed on 14 Jan 2025.
Current net transaction value: -$38,689.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001346164 Primary reporting owner

Simpson Curran

Relationship: Chief Executive Officer, Director
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Tax liability

Transaction value: $38,689
Shares: -4,701
Change %: -1.8%
Price: $8.23
Shares after: 252,331
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2025.